Records containing: Schizoaffective Disorder
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2015-04-17A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2015-04-15An Open-Label Study Changing Generic Clozapine Formulation to FazaClo® (Clozapine, USP) Orally Disintegrating Tablets in Stable Patients With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2015-04-14Determination of Adherence in Patients Admitted to a Psychiatric Unit for Decompensated Psychosis: an Analysis of Serum Levels of Antipsychotics.
-
CLINICAL_TRIALS study record update · 2015-04-10Mindfulness as a Rehabilitation Strategy in Schizophrenia
-
CLINICAL_TRIALS study record update · 2015-04-07A Study of Strategies to Improve Schizophrenia Treatment
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2015-04-07Improving Antipsychotic Adherence Among Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2015-04-07Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)
-
CLINICAL_TRIALS study record update · 2015-04-06Functional Rehabilitation of Older Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2015-04-01Multisite Double-Blind Randomized Controlled Study of Estradiol Plus Antipsychotic Versus Placebo Plus Antipsychotic in the Treatment of Psychotic Symptoms in Women With Schizophrenia
-
CLINICAL_TRIALS study record update · 2015-03-25L-Arginine add-on Treatment for Schizophrenia: A Randomized, Double Blind, Placebo Controlled, Cross Over Study
-
CLINICAL_TRIALS study record update · 2015-03-04A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2015-03-04Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
-
CLINICAL_TRIALS study record update · 2015-02-27The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
-
CLINICAL_TRIALS study record update · 2015-02-04Double Blind Study of Estradiol Plus Neuroleptic Versus Placebo Plus Neuroleptic in the Treatment of Psychotic Symptoms in Women With Schizophrenia
-
CLINICAL_TRIALS study record update · 2015-01-30Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?
-
CLINICAL_TRIALS study record update · 2015-01-26REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2015-01-16A Single-center Safety and Tolerability Study to Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2015-01-16A Randomized, Double-Blind, Placebo-Controlled, Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects With Schizophrenia
-
CLINICAL_TRIALS study record update · 2015-01-16A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Either Schizophrenia or Bipolar Disorder With an Optional Open-Label 26-Week Extension Study
-
CLINICAL_TRIALS study record update · 2015-01-08Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI
-
CLINICAL_TRIALS study record update · 2015-01-08Promoting Health and Functioning in Persons With SMI
-
CLINICAL_TRIALS study record update · 2015-01-05A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2014-11-19POC Study of Pipamperone 15mg Added to Stable Risperidone or Paliperidone Treatment in Chronic Schizophrenic and Schizoaffective Patients With Residual Symptoms: a Phase I/IIa, Randomized, Double-blind, Placebo-controlled Trial of 7 Weeks
-
CLINICAL_TRIALS study record update · 2014-11-19Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2014-11-10An Open-Label, Single Ascending Dose Pharmacokinetic and Safety Study of LY03004 Following Escalating Single Intramuscular Injection in Stable Patients With Schizophrenia or Schizoaffective Disorder